Skip to content

Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection

Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03627000
Enrollment
114
Registered
2018-08-13
Start date
2016-10-01
Completion date
2018-04-01
Last updated
2018-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Infections, Bone and Joint Infection, EPIDEMIOLOGY

Brief summary

This study concerns patients having had an infection on their prosthesis (hip, knee,..) and for whom a 2-step exchange of prosthesis has been done. A 2-step exchange consists in explantation of the prosthesis and implementation of a spacer at the first stage, and reimplantation of a new prosthesis in a second stage. Patients with late prosthetic joint infection are at risk for superinfection at the time of reimplantation. The aim is to determine the microbiological epidemiology in patients experiencing failure following reimplantation to establish, based on the drug susceptibilities, which cement could be the most active.

Interventions

OTHERfailure after reimplantation

description of cinical and microbiological failure

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years

Inclusion criteria

* patients with prosthetic joint infection having had a 2-step exchange at least from the reimplantation, between 2013 and 2015.

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
rate of treatment failureOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

Secondary

MeasureTime frameDescription
rate of bacteria involved in microbiological failureOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)description of microbiological failure : bacteria responsible of microbiological failure
rate of clinical failureOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)description of clinical failure

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026